Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Research Report 2026(Status and Outlook)
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne?a mutation in the DMD gene?happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The global Drugs for Duchenne Muscular Dystrophy (DMD) market size was estimated at USD 226.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 11.20% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Drugs for Duchenne Muscular Dystrophy (DMD) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Drugs for Duchenne Muscular Dystrophy (DMD) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Drugs for Duchenne Muscular Dystrophy (DMD) market.
Global Drugs for Duchenne Muscular Dystrophy (DMD) Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
WaVe life Science
Market Segmentation (by Type)
Eteplirsen
Deflazacort
Ataluren
Market Segmentation (by Application)
Hospitals
Clinics
Home Care
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Drugs for Duchenne Muscular Dystrophy (DMD) Market
Overview of the regional outlook of the Drugs for Duchenne Muscular Dystrophy (DMD) Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Drugs for Duchenne Muscular Dystrophy (DMD) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Drugs for Duchenne Muscular Dystrophy (DMD), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Drugs for Duchenne Muscular Dystrophy (DMD) market size was estimated at USD 226.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 11.20% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Drugs for Duchenne Muscular Dystrophy (DMD) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Drugs for Duchenne Muscular Dystrophy (DMD) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Drugs for Duchenne Muscular Dystrophy (DMD) market.
Global Drugs for Duchenne Muscular Dystrophy (DMD) Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
WaVe life Science
Market Segmentation (by Type)
Eteplirsen
Deflazacort
Ataluren
Market Segmentation (by Application)
Hospitals
Clinics
Home Care
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Drugs for Duchenne Muscular Dystrophy (DMD) Market
Overview of the regional outlook of the Drugs for Duchenne Muscular Dystrophy (DMD) Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Drugs for Duchenne Muscular Dystrophy (DMD) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Drugs for Duchenne Muscular Dystrophy (DMD), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Drugs for Duchenne Muscular Dystrophy (DMD)
1.2 Key Market Segments
1.2.1 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type
1.2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Product Life Cycle
3.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Manufacturers (2020-2025)
3.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Manufacturers (2020-2025)
3.5 Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Drugs for Duchenne Muscular Dystrophy (DMD) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Drugs for Duchenne Muscular Dystrophy (DMD) Market Competitive Situation and Trends
3.8.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Concentration Rate
3.8.2 Global 5 and 10 Largest Drugs for Duchenne Muscular Dystrophy (DMD) Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) INDUSTRY CHAIN ANALYSIS
4.1 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Drugs for Duchenne Muscular Dystrophy (DMD) Market
5.7 ESG Ratings of Leading Companies
6 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2020-2025)
6.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2020-2025)
6.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Price by Type (2020-2025)
7 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Sales by Application (2020-2025)
7.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application (2020-2025)
7.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2020-2025)
8 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET SALES BY REGION
8.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region
8.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
8.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
8.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
8.3 North America
8.3.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country
8.3.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country
8.4.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.5.2 Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country
8.6.2 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.7.2 Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET PRODUCTION BY REGION
9.1 Global Production of Drugs for Duchenne Muscular Dystrophy (DMD) by Region(2020-2025)
9.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Region (2020-2025)
9.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Drugs for Duchenne Muscular Dystrophy (DMD) Production
9.4.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2020-2025)
9.4.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production
9.5.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2020-2025)
9.5.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production (2020-2025)
9.6.1 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2020-2025)
9.6.2 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Drugs for Duchenne Muscular Dystrophy (DMD) Production (2020-2025)
9.7.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2020-2025)
9.7.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Sarepta Therapeutics
10.1.1 Sarepta Therapeutics Basic Information
10.1.2 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.1.4 Sarepta Therapeutics Business Overview
10.1.5 Sarepta Therapeutics SWOT Analysis
10.1.6 Sarepta Therapeutics Recent Developments
10.2 PTC Therapeutics
10.2.1 PTC Therapeutics Basic Information
10.2.2 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.2.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.2.4 PTC Therapeutics Business Overview
10.2.5 PTC Therapeutics SWOT Analysis
10.2.6 PTC Therapeutics Recent Developments
10.3 Pfizer
10.3.1 Pfizer Basic Information
10.3.2 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.3.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.3.4 Pfizer Business Overview
10.3.5 Pfizer SWOT Analysis
10.3.6 Pfizer Recent Developments
10.4 Bristol-Myers Squibb
10.4.1 Bristol-Myers Squibb Basic Information
10.4.2 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.4.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.4.4 Bristol-Myers Squibb Business Overview
10.4.5 Bristol-Myers Squibb Recent Developments
10.5 Italfarmaco
10.5.1 Italfarmaco Basic Information
10.5.2 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.5.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.5.4 Italfarmaco Business Overview
10.5.5 Italfarmaco Recent Developments
10.6 Santhera Pharmaceuticals
10.6.1 Santhera Pharmaceuticals Basic Information
10.6.2 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.6.4 Santhera Pharmaceuticals Business Overview
10.6.5 Santhera Pharmaceuticals Recent Developments
10.7 WaVe life Science
10.7.1 WaVe life Science Basic Information
10.7.2 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.7.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.7.4 WaVe life Science Business Overview
10.7.5 WaVe life Science Recent Developments
11 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET FORECAST BY REGION
11.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast
11.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country
11.2.3 Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Region
11.2.4 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Drugs for Duchenne Muscular Dystrophy (DMD) by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2026-2035)
12.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2026-2035)
12.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Application (2026-2035)
12.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) Forecast by Application
12.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Drugs for Duchenne Muscular Dystrophy (DMD)
1.2 Key Market Segments
1.2.1 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type
1.2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Product Life Cycle
3.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Manufacturers (2020-2025)
3.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Manufacturers (2020-2025)
3.5 Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Drugs for Duchenne Muscular Dystrophy (DMD) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Drugs for Duchenne Muscular Dystrophy (DMD) Market Competitive Situation and Trends
3.8.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Concentration Rate
3.8.2 Global 5 and 10 Largest Drugs for Duchenne Muscular Dystrophy (DMD) Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) INDUSTRY CHAIN ANALYSIS
4.1 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Drugs for Duchenne Muscular Dystrophy (DMD) Market
5.7 ESG Ratings of Leading Companies
6 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2020-2025)
6.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2020-2025)
6.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Price by Type (2020-2025)
7 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Sales by Application (2020-2025)
7.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application (2020-2025)
7.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2020-2025)
8 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET SALES BY REGION
8.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region
8.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
8.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
8.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
8.3 North America
8.3.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country
8.3.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country
8.4.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.5.2 Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country
8.6.2 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.7.2 Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET PRODUCTION BY REGION
9.1 Global Production of Drugs for Duchenne Muscular Dystrophy (DMD) by Region(2020-2025)
9.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Region (2020-2025)
9.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Drugs for Duchenne Muscular Dystrophy (DMD) Production
9.4.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2020-2025)
9.4.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production
9.5.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2020-2025)
9.5.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production (2020-2025)
9.6.1 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2020-2025)
9.6.2 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Drugs for Duchenne Muscular Dystrophy (DMD) Production (2020-2025)
9.7.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2020-2025)
9.7.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Sarepta Therapeutics
10.1.1 Sarepta Therapeutics Basic Information
10.1.2 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.1.4 Sarepta Therapeutics Business Overview
10.1.5 Sarepta Therapeutics SWOT Analysis
10.1.6 Sarepta Therapeutics Recent Developments
10.2 PTC Therapeutics
10.2.1 PTC Therapeutics Basic Information
10.2.2 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.2.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.2.4 PTC Therapeutics Business Overview
10.2.5 PTC Therapeutics SWOT Analysis
10.2.6 PTC Therapeutics Recent Developments
10.3 Pfizer
10.3.1 Pfizer Basic Information
10.3.2 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.3.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.3.4 Pfizer Business Overview
10.3.5 Pfizer SWOT Analysis
10.3.6 Pfizer Recent Developments
10.4 Bristol-Myers Squibb
10.4.1 Bristol-Myers Squibb Basic Information
10.4.2 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.4.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.4.4 Bristol-Myers Squibb Business Overview
10.4.5 Bristol-Myers Squibb Recent Developments
10.5 Italfarmaco
10.5.1 Italfarmaco Basic Information
10.5.2 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.5.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.5.4 Italfarmaco Business Overview
10.5.5 Italfarmaco Recent Developments
10.6 Santhera Pharmaceuticals
10.6.1 Santhera Pharmaceuticals Basic Information
10.6.2 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.6.4 Santhera Pharmaceuticals Business Overview
10.6.5 Santhera Pharmaceuticals Recent Developments
10.7 WaVe life Science
10.7.1 WaVe life Science Basic Information
10.7.2 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.7.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.7.4 WaVe life Science Business Overview
10.7.5 WaVe life Science Recent Developments
11 DRUGS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD) MARKET FORECAST BY REGION
11.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast
11.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country
11.2.3 Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Region
11.2.4 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Drugs for Duchenne Muscular Dystrophy (DMD) by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2026-2035)
12.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2026-2035)
12.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Application (2026-2035)
12.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) Forecast by Application
12.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Table 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
Table 5. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Comparison by Region (M USD)
Table 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) as of 2025)
Table 11. Global Market Drugs for Duchenne Muscular Dystrophy (DMD) Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Drugs for Duchenne Muscular Dystrophy (DMD) Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Type (K MT)
Table 27. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Table 28. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Type (2020-2025)
Table 29. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2020-2025)
Table 30. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type (2020-2025)
Table 31. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2020-2025)
Table 32. Global Drugs for Duchenne Muscular Dystrophy (DMD) Price (USD/KG) by Type (2020-2025)
Table 33. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Application
Table 34. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
Table 35. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Application (2020-2025) & (K MT)
Table 36. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2020-2025)
Table 37. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2020-2025) & (M USD)
Table 38. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2020-2025)
Table 39. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2020-2025)
Table 40. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region (2020-2025) & (K MT)
Table 41. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region (2020-2025)
Table 42. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025) & (M USD)
Table 43. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025)
Table 44. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2020-2025) & (K MT)
Table 45. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2020-2025) & (K MT)
Table 47. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025) & (M USD)
Table 50. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2020-2025) & (K MT)
Table 51. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025) & (M USD)
Table 54. Global Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) by Region(2020-2025)
Table 55. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Region (2020-2025)
Table 57. Global Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Sarepta Therapeutics Basic Information
Table 63. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 64. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Sarepta Therapeutics Business Overview
Table 66. Sarepta Therapeutics SWOT Analysis
Table 67. Sarepta Therapeutics Recent Developments
Table 68. PTC Therapeutics Basic Information
Table 69. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 70. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. PTC Therapeutics Business Overview
Table 72. PTC Therapeutics SWOT Analysis
Table 73. PTC Therapeutics Recent Developments
Table 74. Pfizer Basic Information
Table 75. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 76. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Pfizer Business Overview
Table 78. Pfizer SWOT Analysis
Table 79. Pfizer Recent Developments
Table 80. Bristol-Myers Squibb Basic Information
Table 81. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 82. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Bristol-Myers Squibb Business Overview
Table 84. Bristol-Myers Squibb Recent Developments
Table 85. Italfarmaco Basic Information
Table 86. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 87. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Italfarmaco Business Overview
Table 89. Italfarmaco Recent Developments
Table 90. Santhera Pharmaceuticals Basic Information
Table 91. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 92. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Santhera Pharmaceuticals Business Overview
Table 94. Santhera Pharmaceuticals Recent Developments
Table 95. WaVe life Science Basic Information
Table 96. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 97. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. WaVe life Science Business Overview
Table 99. WaVe life Science Recent Developments
Table 100. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Region (2026-2035) & (K MT)
Table 101. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Region (2026-2035) & (M USD)
Table 102. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Country (2026-2035) & (K MT)
Table 103. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2026-2035) & (M USD)
Table 104. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Country (2026-2035) & (K MT)
Table 105. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2026-2035) & (M USD)
Table 106. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Region (2026-2035) & (K MT)
Table 107. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Region (2026-2035) & (M USD)
Table 108. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Country (2026-2035) & (K MT)
Table 109. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2026-2035) & (M USD)
Table 110. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Country (2026-2035) & (Units)
Table 111. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2026-2035) & (M USD)
Table 112. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Type (2026-2035) & (K MT)
Table 113. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Type (2026-2035) & (M USD)
Table 114. Global Drugs for Duchenne Muscular Dystrophy (DMD) Price Forecast by Type (2026-2035) & (USD/KG)
Table 115. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) Forecast by Application (2026-2035)
Table 116. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Table 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
Table 5. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Comparison by Region (M USD)
Table 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) as of 2025)
Table 11. Global Market Drugs for Duchenne Muscular Dystrophy (DMD) Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Drugs for Duchenne Muscular Dystrophy (DMD) Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Type (K MT)
Table 27. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Table 28. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Type (2020-2025)
Table 29. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2020-2025)
Table 30. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type (2020-2025)
Table 31. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2020-2025)
Table 32. Global Drugs for Duchenne Muscular Dystrophy (DMD) Price (USD/KG) by Type (2020-2025)
Table 33. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Application
Table 34. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
Table 35. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Application (2020-2025) & (K MT)
Table 36. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2020-2025)
Table 37. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2020-2025) & (M USD)
Table 38. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2020-2025)
Table 39. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2020-2025)
Table 40. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region (2020-2025) & (K MT)
Table 41. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region (2020-2025)
Table 42. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025) & (M USD)
Table 43. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025)
Table 44. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2020-2025) & (K MT)
Table 45. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2020-2025) & (K MT)
Table 47. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025) & (M USD)
Table 50. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2020-2025) & (K MT)
Table 51. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025) & (M USD)
Table 54. Global Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) by Region(2020-2025)
Table 55. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Region (2020-2025)
Table 57. Global Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Sarepta Therapeutics Basic Information
Table 63. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 64. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Sarepta Therapeutics Business Overview
Table 66. Sarepta Therapeutics SWOT Analysis
Table 67. Sarepta Therapeutics Recent Developments
Table 68. PTC Therapeutics Basic Information
Table 69. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 70. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. PTC Therapeutics Business Overview
Table 72. PTC Therapeutics SWOT Analysis
Table 73. PTC Therapeutics Recent Developments
Table 74. Pfizer Basic Information
Table 75. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 76. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Pfizer Business Overview
Table 78. Pfizer SWOT Analysis
Table 79. Pfizer Recent Developments
Table 80. Bristol-Myers Squibb Basic Information
Table 81. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 82. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Bristol-Myers Squibb Business Overview
Table 84. Bristol-Myers Squibb Recent Developments
Table 85. Italfarmaco Basic Information
Table 86. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 87. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Italfarmaco Business Overview
Table 89. Italfarmaco Recent Developments
Table 90. Santhera Pharmaceuticals Basic Information
Table 91. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 92. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Santhera Pharmaceuticals Business Overview
Table 94. Santhera Pharmaceuticals Recent Developments
Table 95. WaVe life Science Basic Information
Table 96. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 97. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. WaVe life Science Business Overview
Table 99. WaVe life Science Recent Developments
Table 100. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Region (2026-2035) & (K MT)
Table 101. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Region (2026-2035) & (M USD)
Table 102. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Country (2026-2035) & (K MT)
Table 103. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2026-2035) & (M USD)
Table 104. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Country (2026-2035) & (K MT)
Table 105. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2026-2035) & (M USD)
Table 106. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Region (2026-2035) & (K MT)
Table 107. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Region (2026-2035) & (M USD)
Table 108. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Country (2026-2035) & (K MT)
Table 109. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2026-2035) & (M USD)
Table 110. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Country (2026-2035) & (Units)
Table 111. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2026-2035) & (M USD)
Table 112. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Type (2026-2035) & (K MT)
Table 113. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Type (2026-2035) & (M USD)
Table 114. Global Drugs for Duchenne Muscular Dystrophy (DMD) Price Forecast by Type (2026-2035) & (USD/KG)
Table 115. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) Forecast by Application (2026-2035)
Table 116. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Drugs for Duchenne Muscular Dystrophy (DMD)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD), 2025-2035
Figure 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) (2020-2035)
Figure 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) Product Life Cycle
Figure 13. Drugs for Duchenne Muscular Dystrophy (DMD) Sales Share by Manufacturers in 2025
Figure 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Manufacturers in 2025
Figure 15. Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Drugs for Duchenne Muscular Dystrophy (DMD) Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in 2025
Figure 18. Industry Chain Map of Drugs for Duchenne Muscular Dystrophy (DMD)
Figure 19. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market PEST Analysis
Figure 20. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type
Figure 27. Sales Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2020-2025)
Figure 28. Sales Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type in 2025
Figure 29. Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2020-2025)
Figure 30. Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application
Figure 33. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2020-2025)
Figure 34. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application in 2025
Figure 35. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2020-2025)
Figure 36. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application in 2025
Figure 37. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2020-2025)
Figure 38. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region (2020-2025)
Figure 39. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025)
Figure 40. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Country in 2024
Figure 43. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country in 2024
Figure 45. U.S. Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Country in 2024
Figure 53. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country in 2024
Figure 55. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region in 2024
Figure 67. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region in 2024
Figure 68. China Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (K MT)
Figure 79. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Country in 2024
Figure 80. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (M USD)
Figure 81. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country in 2024
Figure 82. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region in 2024
Figure 92. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Drugs for Duchenne Muscular Dystrophy (DMD) Production Market Share by Region (2020-2025)
Figure 103. North America Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2020-2025)
Figure 106. China Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Type (2026-2035)
Figure 111. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Application (2026-2035)
Figure 112. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Drugs for Duchenne Muscular Dystrophy (DMD)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD), 2025-2035
Figure 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) (2020-2035)
Figure 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) Product Life Cycle
Figure 13. Drugs for Duchenne Muscular Dystrophy (DMD) Sales Share by Manufacturers in 2025
Figure 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Manufacturers in 2025
Figure 15. Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Drugs for Duchenne Muscular Dystrophy (DMD) Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in 2025
Figure 18. Industry Chain Map of Drugs for Duchenne Muscular Dystrophy (DMD)
Figure 19. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market PEST Analysis
Figure 20. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type
Figure 27. Sales Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2020-2025)
Figure 28. Sales Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type in 2025
Figure 29. Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2020-2025)
Figure 30. Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application
Figure 33. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2020-2025)
Figure 34. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application in 2025
Figure 35. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2020-2025)
Figure 36. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application in 2025
Figure 37. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2020-2025)
Figure 38. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region (2020-2025)
Figure 39. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2020-2025)
Figure 40. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Country in 2024
Figure 43. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country in 2024
Figure 45. U.S. Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Country in 2024
Figure 53. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country in 2024
Figure 55. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region in 2024
Figure 67. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region in 2024
Figure 68. China Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (K MT)
Figure 79. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Country in 2024
Figure 80. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (M USD)
Figure 81. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country in 2024
Figure 82. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region in 2024
Figure 92. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Drugs for Duchenne Muscular Dystrophy (DMD) Production Market Share by Region (2020-2025)
Figure 103. North America Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2020-2025)
Figure 106. China Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Type (2026-2035)
Figure 111. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Application (2026-2035)
Figure 112. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Application (2026-2035)
